Skip to content Skip to sidebar Skip to footer

Newsletter

Large Caps Uncategorized

Transurban (ASX:TCL): Its Sydney monopolies are safe (for now), but its branching out into other markets too

Transurban (ASX:TCL) is a unique stock on the ASX. No other stock has such long-term monopolies as Transurban does on its toll roads. Nor is any other stock arguably as hated as much as Transurban, given the constant toll increases. Of course, if you're a monopolist, it doesn't matter if you're liked as long as…

ByNick SundichDecember 11, 2025

Consumer

Myer’s Not Out of Fashion Yet, Relief Rally Lifts Shares 10%

Relief Rally at Myer Myer (ASX:MYR) has had a tough year, falling 62%, but investor sentiment showed early signs of recovery today with shares up 10% following the company’s board presentation. The trading update offered a glimmer of momentum heading into FY26, with total sales for the first 19 weeks of 1H26 up 3 percent,…

ByCharlie YouldenDecember 11, 2025

Market news Mining Stocks

Brazilian Rare Earths (ASX:BRE) Digs Into Value, Amargosa Study Puts Brazil on the Bauxite Map

Brazilian Rare Earths Red-Hot Run Brazilian Rare Earths (ASX: BRE) surged 8% this morning after releasing a positive scoping study for its fully owned Amargosa Bauxite Gallium Project in Bahia, Brazil. The study outlined the potential for Amargosa to become a large scale, low cost direct shipping bauxite operation with strong economics and a 17…

ByCharlie YouldenDecember 11, 2025

Education Education Stocks International Stocks Market news

What does the Fed rate cut mean for Australia? Will it make a difference whether or not the RBA follows suit in 2026?

Many investors will be asking themselves this question: 'What does the Fed rate cut mean for Australia?' This question is always asked, but the answer is a lot less concrete than it would ordinarily be, not least because Australia's RBA will not follow suit, and may even go in a different direction. What are the Best…

ByNick SundichDecember 11, 2025

Tech Stocks Technology

Droneshield’s Back on Investors Radar, But Who’s Really Flying It?

Droneshield Takes Off Again Droneshield (ASX: DRO) shares jumped 16.2% to close at A$2.26, marking a strong rebound after a period of controversy that had weighed on sentiment. The move has sparked plenty of discussion among investors. Is this the start of institutional money rotating back in, or are traders simply taking advantage of short-term…

ByCharlie YouldenDecember 11, 2025

Blue Chip Stocks Consumer Healthcare Stocks

Medibank Private shares have recovered the losses after the cyber breach 2 years ago, but what’s next?

Medibank Private shares took a big hit nearly 3 years ago due to the infamous cyber breach. Investors who chose to buy the dip and have held ever since have done quite well - shares rallied 80% in the following 3 years. But shares have fallen over 12% since August, when it released its FY25 results.…

ByNick SundichDecember 11, 2025

Education

What is a dead cat bounce, how can you identify one and which 5 stocks are in the midst of them?

The term dead cat bounce has gained popularity in recent years. And there have been plenty of examples of this phenomenon on the ASX. So, we thought we'd write an article to explore what exactly is a dead cat bounce in relation to stock investing. What are the Best ASX Stocks to invest in right now? Check…

ByNick SundichDecember 11, 2025

Healthcare Stocks

Is Rhythm Biosciences (ASX:RHY) a Buy After Securing NHS Expertise and US Distribution Deal?

Rhythm Biosciences (ASX: RHY) may finally be turning the corner. The company has secured NHS expertise to support its ColoSTAT bowel cancer blood test launch in the UK, while a separate deal with Catch Bio expands its geneType platform across the United States. For a stock trading at just A$25 to A$30 million market cap,…

ByUjjwal MaheshwariDecember 11, 2025

Gold Stocks

Ramelius Resources (ASX:RMS) Rallies After A$250m Capital Return Program: Should You Buy the Gold Miner?

Ramelius Resources (ASX: RMS) jumped to an intraday high of A$3.71 this week before closing at A$3.57, up 5.6%, after announcing a A$250 million share buyback and doubling its minimum dividend to 2 cents per share. For gold investors, this signals management believes the stock is cheap and cash generation can reward shareholders while funding…

ByUjjwal MaheshwariDecember 11, 2025

Healthcare Stocks

Orthocell (ASX:OCC) Surges 7% on First Hong Kong Sales: Is This Healthcare Stock a Buy as Asian Expansion Accelerates?

Orthocell (ASX: OCC) jumped 7% to A$1.09 on Wednesday after announcing its first commercial sales of Remplir in Hong Kong. The sales, made through distributor MontsMed, follow last month's first surgical case in the region and a strong debut at the Hong Kong Orthopaedic Association's 45th Annual Congress. For investors, this milestone shows the company…

ByUjjwal MaheshwariDecember 11, 2025

the Kick-ass Multipurpose WordPress Theme

Transurban (ASX:TCL): Its Sydney monopolies are safe (for now), but its branching out into other markets too

Myer’s Not Out of Fashion Yet, Relief Rally Lifts Shares 10%

Brazilian Rare Earths (ASX:BRE) Digs Into Value, Amargosa Study Puts Brazil on the Bauxite Map

What does the Fed rate cut mean for Australia? Will it make a difference whether or not the RBA follows suit in 2026?

Droneshield’s Back on Investors Radar, But Who’s Really Flying It?

Medibank Private shares have recovered the losses after the cyber breach 2 years ago, but what’s next?

What is a dead cat bounce, how can you identify one and which 5 stocks are in the midst of them?

Is Rhythm Biosciences (ASX:RHY) a Buy After Securing NHS Expertise and US Distribution Deal?

Ramelius Resources (ASX:RMS) Rallies After A$250m Capital Return Program: Should You Buy the Gold Miner?

Orthocell (ASX:OCC) Surges 7% on First Hong Kong Sales: Is This Healthcare Stock a Buy as Asian Expansion Accelerates?

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here